Article
Endocrinology & Metabolism
Christopher A. Muir, Roderick J. Clifton-Bligh, Georgina Long, Richard A. Scolyer, Serigne N. Lo, Matteo S. Carlino, Venessa H. M. Tsang, Alexander M. Menzies
Summary: Thyroid dysfunction is common following immune checkpoint inhibition, with different subtypes of thyroid immune-related adverse events having unique clinical and biochemical associations. Overt thyrotoxicosis was associated with longer progression free survival and overall survival, while hypothyroidism showed no association with cancer outcomes. Multiple distinct phenotypes of thyroid irAEs suggest potentially different etiologies for thyrotoxicosis and hypothyroidism.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
(2021)
Article
Endocrinology & Metabolism
Christopher A. Muir, Roderick J. Clifton-Bligh, Georgina V. Long, Richard A. Scolyer, Serigne N. Lo, Matteo S. Carlino, Venessa H. M. Tsang, Alexander M. Menzies
Summary: Thyroid dysfunction is common following immune checkpoint inhibition, with distinct phenotypes of thyroid irAEs showing unique clinical and biochemical associations. Overt thyrotoxicosis was associated with longer survival outcomes, while no association was found between hypothyroidism and cancer outcomes.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
(2021)
Article
Oncology
Difei Lu, Jun Yao, Geheng Yuan, Ying Gao, Junqing Zhang, Xiaohui Guo
Summary: This article investigates the prevalence and demographic characteristics of immune checkpoint inhibitor (ICI)-related thyroid dysfunction (ICI-TD) and explores the risk factors of poor clinical outcomes. It finds that thyroid dysfunction is common in ICI treatment, especially in combination therapy.
Article
Oncology
Woorim Kim, Young-Ah Cho, Dong-Chul Kim, A-Ra Jo, Kyung-Hyun Min, Kyung-Eun Lee
Summary: This study aims to investigate factors associated with thyroid dysfunction in cancer patients receiving PD-1/PD-L1 inhibitors and develop machine learning approaches to predict complications. The results showed smoking history, hypertension, and opioids are associated with thyroid-related adverse events. Machine learning models, particularly random forest, demonstrated good predictive performance for such events.
Article
Oncology
Weibin Wang, Liping Wen, Shitu Chen, Xingyun Su, Zhuochao Mao, Yongfeng Ding, Zhendong Chen, Yiran Chen, Jiaying Ruan, Jun Yang, Jie Zhou, Xiaodong Teng, Thomas J. Fahey, Zhongqi Li, Lisong Teng
Summary: Thyroid autoimmunity is not a protective factor in patients with papillary thyroid carcinoma (PTC), while preoperative TPOAb levels can predict the recurrence of papillary thyroid carcinoma.
FRONTIERS IN ONCOLOGY
(2022)
Article
Endocrinology & Metabolism
Yukino Katakura, Tomohiko Kimura, Takashi Kusano, Fuminori Tatsumi, Yuichiro Iwamoto, Junpei Sanada, Yoshiro Fushimi, Masashi Shimoda, Kenji Kohara, Shuhei Nakanishi, Kohei Kaku, Tomoatsu Mune, Hideaki Kaneto
Summary: When using immune checkpoint inhibitors for cancer treatment, patients may experience various immune-related adverse events (irAEs) that need to be promptly identified and managed to avoid compromising the effectiveness of treatment.
FRONTIERS IN ENDOCRINOLOGY
(2021)
Review
Endocrinology & Metabolism
Christopher A. Muir, Venessa H. M. Tsang, Alexander M. Menzies, Roderick J. Clifton-Bligh
Summary: The translated article introduces immune checkpoints, immune checkpoint inhibitors, and the association of thyroid dysfunction with immune-related adverse events (irAEs). Thyroid irAEs may be associated with increased immune toxicity in other organ systems and longer progression-free and overall survival.
FRONTIERS IN ENDOCRINOLOGY
(2022)
Article
Endocrinology & Metabolism
Tina Mosaferi, Karen Tsai, Samantha Sovich, Holly Wilhalme, Nikhita Kathuria-Prakash, Stephanie S. Praw, Alexandra Drakaki, Trevor E. Angell, Melissa G. Lechner
Summary: Patients with ICI-associated hypothyroidism have different thyroid hormone dosing requirements than patients with HT. Based on our findings and prior reports, we recommend that in patients with ICI-associated thyroiditis LT4 therapy be started at an initial weight-based dose of 1.45 mcg/[kg center dot day] once serum free thyroxine levels fall below the reference range.
Article
Biochemistry & Molecular Biology
Yi Li, Yue Zang, Tianda Fan, Zhaochen Li, Anzi Li, Wei Lv, Qingqing Wang, Qinglan Li, Yuanyuan Li, Quan Li, Zhongsheng Sun, Huajing Teng
Summary: This study reveals shared molecular signatures underlying thyroid dysfunction between patients receiving anti-PD-1/PD-L1 inhibitors and PTC patients suffering from Hashimoto thyroiditis, which may provide insights into managing adverse events during cancer immunotherapy.
COMPUTATIONAL AND STRUCTURAL BIOTECHNOLOGY JOURNAL
(2022)
Review
Endocrinology & Metabolism
Alexandra Chera, Andreea Lucia Stancu, Octavian Bucur
Summary: Immune checkpoint inhibitors are effective in cancer treatment, but can lead to immune-related adverse events, including thyroid dysfunction. Early prediction and detection of these events are crucial, as they can serve as prognostic markers and indicators of treatment response.
FRONTIERS IN ENDOCRINOLOGY
(2022)
Article
Oncology
Jae-Won Hyun, Ki Hoon Kim, Su-Hyun Kim, Ho Jin Kim
Summary: This study evaluated the occurrence and management of neuromuscular irAEs induced by ICIs at the National Cancer Center in Korea, and found that while rare, these irAEs can have devastating outcomes.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
(2023)
Article
Endocrinology & Metabolism
Christian Zinck Jensen, Jeppe Lerche la Cour, Torquil Watt, Jorgen Kim Kanters, Henrik Enghusen Poulsen, Jens Faber, Christina Ellervik, Birte Nygaard
Summary: This study found that patients receiving LT4 treatment had an increased prevalence of antidepressant use, rather than those with TPOAb positivity. The results do not support thyroid autoimmunity as a significant factor for antidepressant use in patients receiving LT4 treatment.
Review
Endocrinology & Metabolism
Linghuan Wang, Binqi Li, He Zhao, Peixin Wu, Qingzhen Wu, Kang Chen, Yiming Mu
Summary: This systematic review and meta-analysis evaluated the incidence, evaluation, and management of interferon and endocrine side effects. The study found a higher incidence of hypothyroidism and hyperthyroidism in patients treated with interferon, particularly in combination with ribavirin.
FRONTIERS IN ENDOCRINOLOGY
(2022)
Article
Immunology
Li Zeng, Gang Ma, Kai Chen, Qiao Zhou
Summary: This study examined the trend of ICIs-associated rheumatic irAEs using bibliometric methods, finding that the United States is the leading contributor and observing shifts in research focus through keyword analysis and citation bursts.
FRONTIERS IN IMMUNOLOGY
(2023)
Article
Oncology
David Hsiehchen, Abdul Rafeh Naqash, Magdalena Espinoza, Mitchell S. Von Itzstein, Alessio Cortellini, Biagio Ricciuti, Dwight H. Owen, Mehak Laharwal, Yukihiro Toi, Michael Burke, Yang Xie, David E. Gerber
Summary: The timing of immune-related adverse events (irAE) associated with immune checkpoint inhibitors (ICI) varies greatly. Late-onset irAE is associated with better clinical outcomes compared to early-onset irAE.
Review
Dermatology
Alexander H. R. Varey, Gabrielle J. Williams, Serigne N. Lo, Cecilia Y. Taing, Andrea Maurichi, Mario Santinami, Richard A. Scolyer, John F. Thompson
Summary: This review evaluated the management and prognostic utility of excision margins and sentinel node biopsy (SNB) for patients with melanocytic tumors of uncertain or low malignant potential. The findings indicate a lack of clear guidance on optimal excision margins and the limited prognostic value of SNB for this tumor type. Therefore, routine SNB should not be offered for these tumors.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
(2023)
Letter
Pathology
Elizabeth Paver, Karina Aivazian, Fiona Maciean, Georgina V. Long, Andrew J. Spilane, James S. Wilmott, Richard A. Scolyer
Letter
Pathology
Elizabeth Paver, Karina Aivazian, Fiona Maclean, Georgina Long, Andrew J. Spillane, James S. Wilmott, Richard A. Scolyer
Article
Oncology
J. M. Versluis, A. M. Menzies, K. Sikorska, E. A. Rozeman, R. P. M. Saw, W. J. van Houdt, H. Eriksson, W. M. C. Klop, S. Ch'ng, J. V. van Thienen, H. Mallo, M. Gonzalez, A. Torres Acosta, L. G. Grijpink-Ongering, A. van der Wal, A. Bruining, B. A. van de Wiel, R. A. Scolyer, J. B. A. G. Haanen, T. N. Schumacher, A. C. J. van Akkooi, G. V. Long, C. U. Blank
Summary: Neoadjuvant ipilimumab plus nivolumab has shown high short-term survival rates in patients with macroscopic stage III melanoma, especially for those with a pathologic response. Pathologic response is the strongest predictor for long-term outcome.
ANNALS OF ONCOLOGY
(2023)
Article
Pathology
Nigel G. Maher, Richard A. Scolyer, Andrew J. Colebatch
Summary: Acquired and congenital melanocytic naevi are common benign neoplasms, and understanding their biology and genetics can help diagnose melanocytic tumours correctly and gain insights into naevus aetiology and melanomagenesis.
Article
Pathology
R. V. Rawson, I. A. Vergara, J. R. Stretch, R. P. M. Saw, J. F. Thompson, S. N. LO, R. A. Scolyer, K. J. Busam
Summary: Desmoplastic melanoma (DM) is a rare subtype of melanoma with distinct features. Studies have shown that pure desmoplastic melanoma (PDM) has a lower sentinel lymph node biopsy (SLNB)-positivity rate compared to mixed desmoplastic melanoma (MDM) and non-DM. Therefore, SLNB may not be necessary in PDM patients.
Article
Pathology
Cecilia Lezcano, Marianne Berwick, Li Luo, Raymond Barnhill, Lyn M. Duncan, Pedram Gerami, Lori Lowe, Jane L. Messina, Richard A. Scolyer, Benjamin Wood, Iwei Yeh, Artur Zembowicz, Klaus J. Busam
Summary: Desmoplastic melanoma can be classified into pure and mixed types based on morphological characteristics, which have different risks of lymph node metastasis and distant recurrence. A study showed a substantial interobserver agreement among dermatopathologists in the classification of desmoplastic melanoma, indicating the potential clinical application of this classification as a prognostic factor in melanoma pathology.
Editorial Material
Biochemistry & Molecular Biology
Claus Garbe, Reinhard Dummer, Teresa Amaral, Rodabe N. Amaria, Paolo A. Ascierto, Elizabeth M. Burton, Brigitte Dreno, Alexander M. M. Eggermont, Axel Hauschild, Christoph Hoeller, Roland Kaufmann, Celeste Lebbe, Mario Mandala, Alexander M. Menzies, David Moreno, Olivier Michielin, Paul Nathan, Sapna P. Patel, Caroline Robert, Dirk Schadendorf, Paul C. Lorigan, Richard A. Scolyer, Hussein A. Tawbi, Bart A. van de Wiel, Christian Blank, Georgina V. Long
Summary: Individuals with cutaneous melanoma who receive neoadjuvant immunotherapy demonstrate significant improvement, which should be included in standard care.
Article
Oncology
C. Schmitt, E. P. Hoefsmit, T. Fangmeier, N. Kramer, C. Kabakci, J. Vera Gonzalez, J. M. Versluis, A. Compter, T. Harrer, H. Mijocevic, S. Schubert, T. Hundsberger, A. M. Menzies, R. A. Scolyer, G. V. Long, L. E. French, C. U. Blank, L. M. Heinzerling
Summary: A study of melanoma patients from three countries found no significant association between previous neurotropic infections and immune checkpoint inhibitor-induced neurological adverse events.
CANCER IMMUNOLOGY IMMUNOTHERAPY
(2023)
Article
Medicine, General & Internal
Georgina Long, Susan M. Swetter, Alexander M. Menzies, Jeffrey E. Gershenwald, Richard A. Scolyer
Summary: Cutaneous melanoma is a malignancy derived from skin melanocytes, primarily caused by ultraviolet radiation. Diagnosis is based on clinical and histopathological findings, and treatment options vary depending on disease stage and characteristics. Multidisciplinary care, including systemic drug therapies, has significantly improved melanoma survival rates.
Article
Oncology
Caroline A. Gjorup, Ines Pires da Silva, Linda Martin, Jonathan R. Stretch, Richard A. Scolyer, Georgina Long, Angela Hong
Summary: Two cases of primary desmoplastic melanoma of the nose were successfully treated with anti-PD-1 checkpoint inhibitor and radiation therapy, which provided good outcomes and cosmetic results. This suggests that PD-1 blockade and radiation therapy can be a safe alternative option for desmoplastic melanoma where surgery is morbidly disfiguring.
Article
Dermatology
Elizabeth C. Paver, Tasnia Ahmed, Hazel Burke, Robyn P. M. Saw, Jonathan R. Stretch, Andrew J. Spillane, Kerwin F. Shannon, Ismael A. Vergara, David E. Elder, Serigne N. Lo, John F. Thompson, Richard A. Scolyer
Summary: Ulceration is a key feature in cutaneous melanoma and contributes to staging. However, cases with incipient ulceration do not meet the definition of ulceration and are classified as nonulcerated, leading to interpretive difficulty. The prognostic significance of incipient ulceration in cutaneous melanoma is uncertain.
Meeting Abstract
Oncology
Michael A. Henderson, David Gyorki, Bryan Burmeister, Richard Fisher, Juliana Di Julio, Mark Smithers, Angela Hong, Kerwin Shannon, Richard A. Scolyer, Scott Carruthers, Brendon Coventry, Scott Babington, Joao Duprat, Harald Hoekstra, John Thompson
ANNALS OF SURGICAL ONCOLOGY
(2023)
Meeting Abstract
Oncology
Ismael A. Vergara, Serigne N. Lo, Isabel Li, Alexander M. Menzies, Matteo S. Carlino, Richard A. Scolyer, Georgina V. Long, Ines Pires Da Silva
Meeting Abstract
Oncology
Rebecca C. Simpson, Erin R. Shanahan, Marcel Batten, Ines P. Silva, Irene L. Reijers, Judith M. Versluis, Alexander M. Menzies, Maria Gonzalez, Umaimainthan Palendira, Andrew Holmes, James S. Wilmott, Christian U. Blank, Richard A. Scolyer, Georgina V. Long